E35: Biogen's controversial Alzheimer's drug approval, the billionaire space race, Bitcoin & more
Calacanis, Friedberg, Bezos, Buffett, Chamath Palihapitiya
On the Monday of the FDA approval of Biogen's Aducanumab, three advisory panel members resigned unanimously against the decision as the panel discussed the drug's modest efficacy, its $55,000 annual price point, and the structural incentives for physician prescribing. Concurrently, the discourse expanded to include Jeff Bezos's July 2021 suborbital flight plan, the strategic implications of private space dominance against geopolitical rivals, and the divergent remote work mandates adopted by major tech corporations. Finally, the dialogue examined the socioeconomic fallout from leaked IRS data revealing billionaires paying zero federal income tax, the cultural toxicity observed at the Bitcoin Miami conference, and the proposed need for policy reforms to address housing, healthcare, and education.